Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/06—Phosphorus compounds without P—C bonds
  • C07F9/08—Esters of oxyacids of phosphorus
  • C07F9/09—Esters of phosphoric acids
  • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
  • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
  • C07C309/63—Esters of sulfonic acids
  • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
  • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
  • C07C309/66—Methanesulfonates
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
  • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
  • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
  • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom

Definitions

• the present invention relates to novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumours, and to their use in cell ablation, including gene-directed enzyme-prodrag therapy (GDEPT) and antibody-directed enzymeprodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.
• GDEPT gene-directed enzyme-prodrag therapy
• ADPT antibody-directed enzymeprodrug therapy
• tumour-selective prodrugs reactively inactive compounds that can be selectively converted to more active compounds in vivo
• cancer therapy see, for example Denny, Eur. J. Med. Chem. (2001) 36, 577).
• a prodrug may be converted into an anti-tumour agent under the influence of an enzyme that is linkable to a monoclonal antibody that will bind to a tumour associated antigen.
• an enzyme that is linkable to a monoclonal antibody that will bind to a tumour associated antigen.
• the combination of such a prodrug with such an enzyme monoclonal/antibody conjugate represents a very powerful clinical agent.
• This approach to cancer therapy often referred to as "antibody directed enzyme/prodrug therapy” (ADEPT)
• ADPT antibody directed enzyme/prodrug therapy
• VDEPT virus-directed enzyme prodrug therapy
• Tumour cells are targeted with a viral vector carrying a gene encoding an enzyme capable of activating a prodrug.
• the gene may be transcriptionally regulated by tissue specific promoter or enhancer sequences.
• the viral vector enters tumour cells and expresses the enzyme, in order that a prodrug is converted to an active drug within the tumour cells (Huber et al., Proc. Natl Acad. Sci. USA (1991) 88, 8039).
• non-viral methods for the delivery of genes have been used. Such methods include calcium phosphate co-precipitation, microinjection, liposomes, direct DNA uptake, and receptor- mediated DNA transfer. These are reviewed in Morgan & French, Annu. Rev. Biochem. , 1993, 62; 191.
• GDEPT gene-directed enzyme prodrug therapy
• 4-Nitroaromatic compounds are reduced by both mammalian and bacterial flavoprotein enzymes, which effect stepwise addition of up to six electrons.
• the major enzymatic metabolite is usually the 4-electron reduced species (Tiydroxylamine).
• nitrophenyl mustards and nitrophenylaziridines have been reported as 10 prodrugs for use in gene-directed enzyme-prodrug therapy (GDEPT) in conjunction with nitroreductase enzymes.
• GDEPT gene-directed enzyme-prodrug therapy
• CB 1954 [5-(aziridin-l-yl)-2,4- dinitrobenzamide; (1) [shown below] is reported to be a substrate for the aerobic nitroreductase NTR (nfsB gene product) isolated from E. coli B (Boland et al., Biochem. Pharmacol. 1991, 41, 867-875; Anlezark et al., Biochem. Pharmacol, 15 1992, 44, 2289-2295; Parkinson et al, J. Med. Chem.
• the dinitrophenyl mustard SN 23862 (2) is also a substrate for NTR, and shows selective toxicity towards cell lines that express the enzyme. It is activated by nitro group5 reduction (Palmer et al., J. Med. Chem., 1995, 38, 1229; Kestell et al., Cancer Chemother. Pharmacol., 2000, 46, 365-374).
• the 4-SO 2 Me derivative (3) was also a substrate (Atwell et al., Anti-Cancer Drug Des., 1996, 11, 553), as were the regioisomers (4) and (5) (Friedlos et al., J. Med. Chem., 1997, 40, 1270).
• estramustine phosphate (Estracyt; 6), which has been shown to bind to tubulin binding domains on various microtubule-associated proteins (Moraga et al., Biochim. Biophys. Acta, 1992, 1121, 97-103), and which has been shown to be active in advanced breast cancer (Keren-Rosenberg et al., Semin. Oncol, 1997, 24 (Suppl. 3), 26-29), but has not been shown to be activated by NTR or hypoxia.
• estramustine phosphate to be a radiation sensitizer (Kim et al., Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 555-557).
• the phenol mustard phosphate analogue 7 is a carboxypeptidase substrate that is not activated under hypoxic conditions, (Matsui et al., Japanese Patent 07082280 A2, 1995), and the solubilised mustard 8 has been described as a phosphatase inhibitor but has not been shown to be activated under hypoxic conditions (Workman, Chem.-Biol. Interact., 1978, 20, 103-112).
• the present invention provides novel phosphate compounds of Formula 1
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 ., -NHCO- or -NHSO 2 -;
• R represents a lower C ⁇ _ 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dial lamino and N-oxides therefrom;
• Y represents at any available ring position -N-aziridinyl, -N(CH CH 2 W) 2 or
• each W is independently selected from halogen or -OSO 2 Me.
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me; and pharmaceutically acceptable salts and derivatives thereof.
• the phosphate compound of Formula (I) is selected from a compound represented by formulae (la), (lb) or (Ic)
• Y may represent
• n 1 to 6
• Z represents -N0 2j -halogen, -CN, -CF 3 or -SO 2 Me; and where each W is independently selected from halogen or -OSO 2 Me and pharmaceutically acceptable salts and derivatives thereof.
• the phosphate compound of Formula (I) is selected from the following:
• the present invention provides alcohol compounds of Formula (II)
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 _, -NHCO- or -NHSO 2 -;
• Y represents at any available ring position -N-aziridinyl, -N(CH 2 CH 2 W) 2 , or -N(CH 2 CH MeW) 2 where each W is independently selected from halogen or -OSO 2 Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• R represents a lower C ⁇ _ 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; and pharmaceutically acceptable salts and derivatives thereof, with the proviso that
• the alcohol compound of Formula (II) is selected from a compound represented by formulae (Ha), (Tib) or (lie)
• n 1 to 6 Z represents -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me; and where each W is independently selected from halogen or -OSO Me and pharmaceutically acceptable salts and derivatives thereof with the proviso that
• the compound of Formula (II) is selected from the following:
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 -, -NHCO- or -NHSO 2 -;
• R represents a lower C ⁇ _ 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dial lamino and N-oxides therefrom;
• Y represents at any available ring position -N-aziridinyl or -N(CH 2 CH 2 W) 2 , where each W is independently selected from halogen or -OSO 2 Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 -, -NHCO- or -NHSO 2 -;
• Y represents at any available ring position -N-aziridinyl, -N(CH 2 CH 2 W) 2 , or -N(CH 2 CH MeW) 2 where each W is independently selected from halogen or -OSO 2 Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me; and R represents a lower C ⁇ _ 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom.
• n 1 to 6
• Z represents -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me; and where Wi is halogen and W 2 is -OSO 2 Me and pharmaceutically acceptable salts and derivatives thereof;
• the method including the step of reacting a compound of formulae (ITa'), (lib') or (He') optionally with heating
• W' ⁇ and W 2 are either iodine and/or bromine that the iodine and/or bromine can be partially or completely substituted with-OSO 2 Me.
• W' ⁇ and W' 2 represent chlorine
• the chlorine is inert and cannot be can be substituted with - OSO 2 Me.
• the solvent is selected from MeCN or other polar non-protic solvent.
• Y may represent and wherein n represents 1 to 6
• Z represents -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me; and where each W is independently selected from halogen or -OSO 2 Me and pharmaceutically acceptable salts and derivatives thereof
• Y represents and wherein .
• n 1 to 6
• Z represents -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me; and where each W is independently selected from halogen or -OSO 2 Me and pharmaceutically acceptable salts and derivatives.
• the present invention provides a method for the use as prodrugs suitable for (i) GDEPT (gene-directed enzyme-prodrug therapy) or ADEPT (anti-body directed enzyme prodrug therapy) in conjunction with at least one nitroreductase enzyme; or (ii) Use as one or more hypoxia-selective cytotoxins, including the step of administering a compound of Formula (I) as defined above or a compound of Formula (II)
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 _, -NHCO- or -NHSO 2 -;
• Y represents at any available ring position -N-aziridinyl, -N(CH 2 CH 2 W) 2 , or -N(CH 2 CH Me W) 2 where each W is independently selected from halogen or -OSO Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• R represents a lower C ⁇ . 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dial__ylamino and N-oxides therefrom; and pharmaceutically acceptable salts and derivatives thereof; or a mixture thereof in a therapeutically effective amount to tumour cells in a subject.
• the nitroreductase enzyme is encoded for by the nfsB gene of either E. coli or by orthologous genes in Clostridia species.
• the method includes the further step of irradiating the tumour cells.
• the present invention provides a method for the use as prodrugs suitable for GD ⁇ PT (gene-directed enzyme-prodrug therapy) or ADEPT (antibody- directed enzyme prodrug therapy) in conjunction with at least one nitroreductase enzyme, as an anticancer agent including the step of administering a compound of Formula (I) as defined above or a compound of Formula (II)
• X represents at any available ring position -CONH-, -SO NH-, -O-, -CH 2 -, -NHCO- or -NHSO 2 -;
• Y represents at any available ring position -N-aziridinyl , -N(CH 2 CH 2 W) 2 or -N(CH 2 CH Me ) 2 , where each W is independently selected from halogen or -OSO 2 Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• R represents a lower C_. 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; and pharmaceutically acceptable salts and derivatives thereof; or a mixture thereof in a therapeutically effective amount to target tumour cells in a subject.
• the nitroreductase enzyme is encoded for by the nfsB gene ofE .coli or by orthologous genes in Clostridia species.
• the method includes the further step of irradiating the tumour cells.
• ADEPT it may be necessary to supply a reducing co- factor, because these may not be present in significant concentrations outside cells. It is envisaged that a synthetic co-factor could be used to stimulate activation of the pro-drug by the likes of an intracellular enzyme. The same issue does not arise with GDEPT because there are several intracellular reducing co-factors such as the likes of NADH and NADPH in significant concentrations.
• a method of cell ablation utilising at least one nitroreductase enzyme wherein the method includes .the step of administering a compound of Formula (I) as defined a above or a compound of Formula
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 -, -NHCO- or -NHSO 2 -;
• Y represents at any available ring position -N-aziridinyl, -N(CH 2 CH W) 2 or -N(CH 2 CH Me ) 2 , where each W is independently selected from halogen or -OSO 2 Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• R represents a lower C ⁇ . alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; and pharmaceutically acceptable salts and derivatives thereof, or a mixture thereof in an effective amount to ablate cells, wherein said cells express at least one nitroreductase enzyme.
• the nitroreductase enzyme is encoded for by the nfsB gene in E. coli or by orthologous genes in Clostridia species.
• the cells that are targeted for ablation are tumor cells in tissue in a subject.
• the method of cell ablation utilising at least one nitroreductase enzyme is delivered by either ADEPT or GDEPT technology.
• the cell ablation provides a substantially minimal bystander effect.
• the present invention provides a method of providing anticancer therapy, wherein a compound of Formula (I) as defined above is administered in a therapeutically effective amount to tumour cells in a subject.
• the therapeutically effective amount of said method is between about 20% to 100% of the maximum tolerated dose of said subject.
• the method includes the further step of irradiating the tumour cells.
• a pharmaceutical composition including a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (II)
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 -, -NHCO- or -NHSO 2 -;
• Y represents at any available ring position -N-aziridinyl, -N(CH 2 CH 2 W) 2 or -N(CH 2 CH MeW) 2 .
• W is independently selected from halogen or -OSO 2 Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• R represents a lower Ci_ 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; and pharmaceutically acceptable salts and derivatives thereof, or a mixture thereof, and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.
• the pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser should preferably be non-toxic and should not interfere with the efficacy of the active ingredient.
• the precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, such as cutaneous, subcutaneous, or intravenous. It is to be appreciated that these factors could be readily determined by someone skilled in the art without undue experimentation.
• compositions for oral administration may be in tablet, capsule, powder or liquid form.
• a tablet may comprise a solid carrier or an adjuvent.
• Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
• a capsule may comprise a solid carrier such as gelatin.
• the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has a suitable pH, isotonicity and stability.
• a parenterally acceptable aqueous solution which is pyrogen-free and has a suitable pH, isotonicity and stability.
• Those of relevent skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride injection, Ringer's injection, Lactated Ringer's injection.
• Preservatives, stabilisers, buffers antioxidants and/or other additives may be included as required.
• X represents at any available ring position -CONH-, -SO 2 NH ⁇ , -O-, -CH 2 -, -NHCO- or -NHSO 2 -;
• Y represents at any available ring position -N-aziridinyl, -N(CH 2 CH W) 2 or -N(CH 2 CH MeW) 2 . where each W is independently selected from halogen or -OSO 2 Me;
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• R represents a lower C ⁇ - 6 alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; and pharmaceutically acceptable salts and derivatives thereof, or mixtures thereof, for use in ⁇ GDEPT or (ii) as a hypoxia selective cytotoxin, to target cancer cells in a subject in need thereof.
• X represents at any available ring position -CONH-, -SO 2 NH-, -O-, -CH 2 -, -NHCO- or
• Y represents at any available ring position -N-aziridinyl, -N(CH 2 CH W) 2 or -N(CH 2 CH MeW) 2 .
• W is independently selected from halogen or -OSO 2 Me
• Z represents at any available ring position -NO 2 , -halogen, -CN, -CF 3 or -SO 2 Me;
• R represents a lower alkyl optionally substituted with one or more groups including hydroxy, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; and pharmaceutically acceptable salts and derivatives thereof, or mixtures thereof for use in cell ablation therapy to target cancer cells in a subject in need thereof.
• While the compounds of the present invention will typically be used to target tumour cells or tumour tissues in human subjects, they may be used to target tumour cells or tissues in other warm blooded animal subjects such as other primates, farm animals such as cattle, and sports animals and pets such as horses, dogs, and cats.
• terapéuticaally effective amount is to be understood as an amount of a compound of Formula (I) or Formula (II) as defined above or a compound of any one of compounds Ia-Ic, or Ila-IIc as defined above or a mixture thereof that is sufficient to show benefit to a subject with cancer cells.
• the actual amount, rate and time-course of administration, will depend on the nature and severity of the disease being treated. Prescription of treatment is within the responsibility of general practitioners and other medical doctors.
• halogen includes chlorine, bromine or iodine.
• the compounds of the invention as defined above may be administered alone or in combination with other treatments, especially radiotherapy and cytotoxic chemotherapeutic drugs, either simultaneously or sequentially dependent upon the condition to be treated.
• the pharmaceutically acceptable derivatives and salts thereof include acid derived salts formed from are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic, isethionic acids and the like and base derived salts formed from sodium and potassium carbonate, sodium and potassium hydroxide, ammonia, triemylamine, triemanolamine and the like.
• cell ablation is to be understood as the killing of cells, that have been engineered to express an enzyme, such as a nitroreductase, by administration of a prodrug that is activated by that enzyme.
• cell ablation can be used to selectively ablate specified target cells or tissue through specific enzymatic expression of a nitroreductase for example, that is specifically expressed by the tissue and which can then be employed to activate a prodrug into an active metabolite to ablate the specified target cells or tissue.
• substantially minimal bystander effect is to be understood as meaning that the killing of adjoining non-targeted cells is minimal because there is little or no diffusion between the targeted and non-targeted cells of an activated metabolite that arises from the enzymatic activation of a compound of Formula (I) or Formula (IT) as defined above or a compound of any one of compounds Ia-Ic, or Ila-IIc as defined above or a mixture thereof.
• Pharmaceutically acceptable salts of formula (I) include the basic or acidic compounds of formula (I) that form pharmaceutically acceptable salts with both organic and inorganic acids and/or organic and inorganic bases.
• suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic, isethionic, and the like.
• suitable bases for salt formation are sodium and potassium carbonate, sodium and potassium hydroxide, ammonia, triemylamine, triemanolamine, and the like.
• Y may represent
• Example 1 N-(3-Hydroxypropyl)-5-[bis(2-chloroethyl)amino]-2,4- dinitrobenzamide (IIa-3).
• Example 10 (Scheme 2d). 2-[Bis(2-Chloroethyl)amino]-iV-(2-hydroxyethyl)-3,5- dinitrobenzamide (IIb-2) and 2-[bis(2-bromoethyl)amino]-iV-(2-hydroxyethyl)-3,5- dinitrobenzamide (IIb-7). 2-C oro-3,5-dinitrobenzoic acid (1) (18 g, 81 mmol) was treated with SOCl (250 ml) containing one drop of DMF and heated under reflux for 6 h.
• Example 12 (Scheme 2d). 2-[Bis(2-chloroethyl)amino]-iV " -(4-hydroxybutyl)-3,5- dinitrobenzamide (IIb-4) and 2-[bis(2-bromoethyl)amino]-. ⁇ -(4-hydroxybutyl)-3,5 ⁇ dinitrobenzamide (IIb-9). Reaction of the acid chloride of 11 (2.65 g, 10 mmol) with 4- aminobutanol (1.9 g) as above, followed by acidification to pH 4-5 with 1 N HCl and evaporation of most of the solvent gave a residue. This was partitioned between water (50 mL) and EtOAc (100 mL).
• Example 13 2-[Bis(2-chloroethyl)amino]-iV-(5-hydroxypentyl)-3,5- dinitrobenzamide (Hb-5) and 2-[bis(2-bromoethyl)ammo]-iV-(5-hydroxypentyI)-3,5- dinitrobenzamide (IIb-10).
• Example 16 (Scheme 2f).2 ⁇ ((2-Bromoethyl)-2- ⁇ [(2-hydroxypropyl)amino]carbonyl ⁇ - 4,6-dinitroanilino)ethyl methanesulfonate (Hb-13).
• a solution of 13 (1.22 g, 4.0 mmol) in 50 mL of CH 2 C1 2 was cooled in an ice-bath, and 3,4-dihydro-2H-pyran (1.0 mL) and p- toluenesulfonic acid (0.1 g) were added. The reaction mixture was stirred for 2 h, then concentrated under reduced pressure.
• Example 17 (Scheme 2g).2-((2-bromoethyl)-2- ⁇ [(2-hydroxyethyl)amino]carbonyl ⁇ - 5 4,6-dinitroanilino)ethyl methanesulfonate (Hb-12).
• Solid Hb-7 300 mg, 0.62 mmol
• silver methanesulfonate 130 mg, 0.65 mmol
• the solid AgBr was washed with EtOAc to give a 98% yield of AgBr.
• IIb-2m was prepared by an alternative method as following: A solution of ⁇ b-2 (12.50 g, 31.6 mmol) in 3-methyl-2-butanone (150 mL) was treated at 25 °C with Nal (5.69 g, 38.0 mmol) and the mixture was stirred at 70 °C for 2 h and then concentrated under reduced pressure. The residue was partitioned between water (250 mL) and EtOAc (250 mL) and the separated organic layer was washed with water, dried ( ⁇ a 2 SO 4 ) and then concentrated under reduced pressure.
• Example 21 (Scheme 2j).3-[Bis(2-bromoethyl)amino]-iV-(3-hydroxypropyl)-2,6- dinitrobenzamide (IIc-8) and 2-((2-bromoethyl)-3- ⁇ [(3- hy droxypropyl)amino] carbonyl ⁇ -2,4-dinitroanilino)ethyl methanesulfonate (Hc-13).
• Example 22 (Scheme 2j). 3-[Bis(2-bromoethyl)amino]- ⁇ r -(4-hydroxybutyl)-2,6- dinitrobenzamide (IIc-9) and 2-((2-bromoethyl) ⁇ 3- ⁇ [(4- hydroxybutyl)amino] carbonyl ⁇ -2,4-dinitroanilino)ethyl methanesulfonate (IIc-14).
• Solid IIc-8 (2.15 g, 4.3 mmol) was added to a hot solution of 5 silver methanesulfonate (0.992 g, 4.9 mmol) in dry MeCN (40 mL). The mixture was heated under reflux for 3 h, then cooled and filtered. The solvent was removed at reduced pressure and the residue was separated by chromatography on silica gel, eluting with EtOAc/petroleum ether (from 1 :1 to 1 :0), to give successively IIc-13 (0.5 g, 25%), IIc-8 (0.3 g, 14%) and 27 (0.4 g, 18%).
• Example 26 2-[[2-[Bis(2-bromoethyl)amino]-3,5-dinitrobenzoyl]amino]ethyl dihydrogen phosphate (Ib-7P).
• a solution of alcohol IIb-7 (2.58 g, 5.33 mmol) and di- tert-butyl diethylphosphoramidite (93%, 2.0 mL, 6.9 mmol) in dry DMF (20 mL) under N 2 was treated with IH-tefrazole (3 wt. % in CH 3 CN, 55 mL, 18.7 mmol) and stirred at 20 °C for 1.5 h.
• reaction mixture was then cooled to -50 °C and a solution of 3- chloroperoxybenzoic acid (55%, 2.68 g, 8.54 mmol) was rapidly added such that the temperature was kept below -5 °C.
• the reaction mixture was warmed to room temperature and diluted with CH 2 C1 2 (150 mL). The solution was washed with 5% aqueous Na 2 S O 5 (2 x 50 mL), 10% aqueous NaHCO 3 (2 x 50 mL), water (2 x 50 mL), dried, concentrated under reduced pressure below 30 °C and the residue was shaken with i-Pr 2 O/hexane and refrigerated.
• Example 28 3-[[5-[Bis(2-bromoethyl)amino]-2,4-dinitrobenzoyl]amino]propyl dihydrogen phosphate (Ia-8P). Similar phosphorylation of IIa-8, followed by chromatography of the product on silica gel and elution with CH 2 Cl 2 /EtOAc (1 : 1), gave di-tert-butyl 3-[[5-[bis(2-bromoethyl)amino]-2,4-dinitrobenzoyl]amino]propyl phosphate (Ia-8E) (66%) as a yellow solid: mp (EtOAc/i-Pr 2 O/hexane) 110-111°C (dec).
• Example 37 2-[(2-Bromoethyl)-2,4-dinitro-3-[[[2-(phosphonooxy)ethyl]amino] ⁇ carbonyljanilino] ethyl methanesulfonate (Ic-12P). Similar phosphorylation of IIc-12, followed by chromatography of the product on silica gel and elution with EtOAc/pefroleum ether (from 1:2 to 1:0), gave (Ic-12E) (99%) as a yellow solid: mp (EtOAc/petroleum ether) 82-86 °C (dec).
• Example 39 2-[(2-Iodoethyl)-2,4-dinitro-3-[[[3-(phosphonooxy)propyl] amino]- carbonyfjanilino] ethyl methanesulfonate (Ic-15P).
• Representative alcohols of Formula (I) show selective cytotoxicity towards human cancer cell lines transfected with either the E. coli nitroreductase cDNA (NTR) (Table 3, columns 2 and 3), or human cytochrome P450 reductase (P450R) under hypoxic conditions (Table 3, columns 4 and 5).
• NTR E. coli nitroreductase cDNA
• P450R human cytochrome P450 reductase
• Table 3 cytochrome P450 reductase
• sensitivity ratios are displayed to indicate the degree of selectivity for either NTR expression (column 3) or hypoxia (column 5).
• overexpression of P450R is not required for hypoxic selectivity.
• IC 50 values are derived from cell proliferation experiments, following 4 hour drug exposure under a gas phase of either 20% oxygen or 0% oxygen (anoxia, achieved using an anaerobic chamber). Cells were grown under aerobic conditions for a further 5 days, and cell density estimated using the sulphorhodamine B assay, to determine the concentration of prodrug required to inhibit growth to 50% of control.
• the activity of the phosphates as hypoxic cytotoxins is demonstrated by the data in Figure 1 for the representative example (Ib-7P).
• This employs an in vivo excision assay with the Rif-1 tumour, where the oxic tumour cells are sterilised using 15Gy of radiation, and the cytotoxicity of an agent against the remaining hypoxic cells can be quantitated.
• Ib-7P acts as a hypoxia-selective cytotoxin in vivo. Although less active against oxic tumour cells, this activity is significant demonstrating that the compound also has utility as a single agent (without radiation).
• the notable activity of the phosphates of Formula (I) against hypoxic cells in human tumour xenografts is illustrated by the data of Table 4.
• SiHa human cervical carcinoma cells were grown subcutaneously in CD-I nude (immunodeficient) mice.
• the compounds were administered at doses corresponding to 75% or 20% of the maximum tolerated dose (MTD), 5 minutes after a whole body dose of ionising radiation (cobalt-60 gamma radiation) sufficient to sterilise the oxic cells (15 Gy).
• the tumours were excised 18 hours later, dissociated with a cocktail of proteases, and cell survival was determined using a clonogenic assay.
• Table 4 Activity of phosphates of Formula (I) against oxic and hypoxic cells in SiHa human tumour xenografts in nude mice. Compounds were administered as single i.p. doses in saline.
• phosphates of Formula (I) as NTR activated cytotoxins is provided in Figure 2.
• WiDr in vivo growth delay assay xenografts containing mixtures of WiDr T and WiDr 1 ⁇ 11 cells are grown to 300mm 3 and treated with a single dose of prodrug at its MTD. Tumour growth is monitored over time and animals are euthanased when mean tumour volume >1600mm 3 . Data is presented as time to death.
• the activity of the phosphate (Ib-7P) is observed to exceed that of its parent alcohol (Tfb-7), when administered at their respective maximum tolerated doses (750 ⁇ mol/kg).
• Ib-7P is superior to IIb-7 with respect to (i) time to first treatment failure (77- days vs. 17-days) and (ii) over-all survival (40% vs. 6%).
• Figure 2 In vivo activity of IIb-7 and its corresponding phosphate pre-prodrug, Ib-7P, against human colon carcinoma xenografts grown by inoculating mixtures of 90% NTR - ve and 10% NTR+ve Wi Dr cells.
• Cmpd lb-2mP (1.333 mmol/kg, i.p., female CD-1 nude mice)
• Cmpd lb-7P (0.562 mmol/kg, i.p., female CD-1 nude mice)
• the data shows that the phosphate esters are converted efficiently to the corresponding alcohols in mice.
• the alcohols are the species activated by nifroreduction in hypoxic, or NTR-expressing, cells.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Radiation-Therapy Devices (AREA)

Priority Applications (10)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=34555019

Family Applications (1)

Country Status (10)

Cited By (12)

Families Citing this family (13)

Citations (3)

Family Cites Families (2)

• 2004
  • 2004-10-29 JP JP2006537921A patent/JP4760712B2/ja not_active Expired - Fee Related
  • 2004-10-29 WO PCT/NZ2004/000275 patent/WO2005042471A1/en not_active Ceased
  • 2004-10-29 AU AU2004285831A patent/AU2004285831B2/en not_active Ceased
  • 2004-10-29 EP EP04817434A patent/EP1680394A4/en not_active Withdrawn
  • 2004-10-29 BR BRPI0416085-1A patent/BRPI0416085A/pt not_active IP Right Cessation
  • 2004-10-29 CA CA002544335A patent/CA2544335A1/en not_active Abandoned
  • 2004-10-29 KR KR1020067010566A patent/KR101167335B1/ko not_active Expired - Fee Related
  • 2004-10-29 RU RU2006118785/04A patent/RU2372324C2/ru not_active IP Right Cessation
  • 2004-10-29 US US10/577,078 patent/US7629332B2/en not_active Expired - Fee Related
• 2006
  • 2006-04-11 IL IL175000A patent/IL175000A0/en unknown
• 2009
  • 2009-08-11 US US12/461,419 patent/US20100010094A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (13)

Also Published As

Similar Documents

Legal Events